The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monick, M. M.
Right arrow Articles by Hunninghake, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monick, M. M.
Right arrow Articles by Hunninghake, G. W.
The Journal of Immunology, 2006, 177: 1636-1645.
Copyright © 2006 by The American Association of Immunologists

Active ERK Contributes to Protein Translation by Preventing JNK-Dependent Inhibition of Protein Phosphatase 11

Martha M. Monick2, Linda S. Powers, Thomas J. Gross, Dawn M. Flaherty, Christopher W. Barrett and Gary W. Hunninghake

University of Iowa Carver College of Medicine and Veterans Administration Medical Center, Iowa City, IA 52242


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Human alveolar macrophages, central to immune responses in the lung, are unique in that they have an extended life span in contrast to precursor monocytes. We have shown previously that the ERK MAPK (ERK) pathway is constitutively active in human alveolar macrophages and contributes to the prolonged survival of these cells. We hypothesized that ERK maintains survival, in part, by positively regulating protein translation. In support of this hypothesis, we have found novel links among ERK, JNK, protein phosphatase 1 (PP1), and the eukaryotic initiation factor (eIF) 2{alpha}. eIF2{alpha} is active when hypophosphorylated and is essential for initiation of protein translation (delivery of initiator tRNA charged with methionine to the ribosome). Using [35S]methionine labeling, we found that ERK inhibition significantly decreased protein translation rates in alveolar macrophages. Decreased protein translation resulted from phosphorylation (and inactivation) of eIF2{alpha}. We found that ERK inhibition increased JNK activity. JNK in turn inactivated (via phosphorylation) PP1, the phosphatase responsible for maintaining the hypophosphorylated state of eIF2{alpha}. As a composite, our data demonstrate that in human alveolar macrophages, constitutive ERK activity positively regulates protein translation via the following novel pathway: active ERK inhibits JNK, leading to activation of PP1{alpha}, eIF2{alpha} dephosphorylation, and translation initiation. This new role for ERK in alveolar macrophage homeostasis may help to explain the survival characteristic of these cells within their unique high oxygen and stress microenvironment.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Human alveolar macrophages survive for long periods in the lung (1). Survival occurs even in the face of exposure to chemical pollutants, reactive oxygen species, inflammatory mediators, and infectious agents (2). This ability to adapt to stress is crucial to their survival. We have shown that human alveolar macrophages are characterized by high constitutive activity of two survival pathways, PI3K/protein kinase B (Akt) and ERK MAPK (3). The survival effects of Akt are well described and include inhibition of BH3-only proapoptotic proteins, caspases, and the transcription factor, FoxOa (4, 5). The survival mechanisms of ERK activity are less well described and appear to be cell type and system specific. Although ERK has been linked to apoptosis in a few cases (6), in the majority of studies, ERK activity is linked to cell survival, and the specific mechanisms of its survival activity are unknown (3, 7, 8, 9, 10, 11).

ERK is a member of the MAPK family of serine/threonine kinases. It is activated by phosphorylation of a tyrosine x threonine motif (TEY) and in turn phosphorylates downstream substrates containing a consensus proline-directed serine or threonine site (PX(S/T)P) (12, 13). Among known ERK substrates are a number of proapoptotic proteins that are inhibited by ERK activity (caspase 9 and BimEL) (14, 15). ERK has also been shown to contribute to cell survival via other mechanisms. In one case, ERK has been shown to regulate Hdm2 protein expression (Hdm2 inhibits p53 accumulation) by enhancing association of HDM2 transcripts with polyribosomes (16). This effect of ERK on protein translation led to our present hypothesis that in human alveolar macrophages constitutive ERK activity positively regulates protein translation and survival.

Ongoing protein translation is important for the continued health of cells and is regulated at a number of points, including initiation, elongation, and termination. The primary rate-limiting step is initiation of translation, and this is regulated at multiple checkpoints (17). Stresses, including DNA damage, misfolded proteins, nutrient deprivation, and viral infection, induce a temporary shutdown of the translation machinery (17). In addition to the temporary shutdown of translation induced by stress, a prolonged shutdown of protein translation accompanies apoptosis generated by many stimuli (18, 19). The prolonged survival of alveolar macrophages suggests ongoing functional translation machinery.

The two main pathways leading to initiation of translation are the eukaryotic initiation factor (eIF)3 4E pathway that brings mRNAs with 5' caps to the ribosome and the eIF2 pathway that is responsible for bringing the initiator methionyl-tRNA (Met-tRNAimet) to the start site. ERK activity is already linked in some systems to translation initiation via a described effect on Mnk1 phosphorylation of eIF4E (20). In contrast to the described link between ERK and eIF4E, there is no described link between ERK signaling and the eIF2 pathway (17, 21, 22, 23). In preliminary studies, we found no effect of ERK on the eIF4E pathway in human alveolar macrophages, but we did find that ERK activity modulated the phosphorylation state of eIF2{alpha} (dephosphorylation of serine 51 is required for activity).

Four kinases have been described that can phosphorylate serine 51 on eIF2{alpha} and decrease protein translation after stress (24). Protein kinase R (PKR) is activated by dimerization following exposure to dsRNA (25). Heme-regulated inhibitor kinase (HRI) is activated by low heme levels (26). PKR-like endoplasmic reticulum kinase (PERK) senses endoplasmic reticulum (ER) stress (27) and general control nonderepressing 2 kinase (GCN2) responds to amino acid deprivation (28). Activation of any of these kinases can lead to eIF2{alpha} phosphorylation on serine 51 and decreased protein translation. The exceptions to this block in translation are a few stress-related proteins whose translation actually goes up in the setting of eIF2{alpha} phosphorylation (17). As well as the described kinases, the phosphorylation and activity of eIF2{alpha} are also regulated by the activity of protein phasphatase 1{alpha} (PP1{alpha}) phosphatase (29). The balance between upstream kinase activity and PP1{alpha} phosphatase activity determines the translation outcome (21).

This study was performed in human alveolar macrophages obtained from normal volunteers. Alveolar macrophages are a distinct cell population with a unique environment. They are both similar to and distinct from other macrophage populations. We have recently shown differences in survival pathways between alveolar macrophages and their precursors, blood monocytes (3, 30). In both studies, we found that alveolar macrophages have constitutive activity of ERK and the PI3K/Akt pathways that is not present in monocytes. The role of the baseline ERK activity is the focus of this study. There are other studies that define important differences between alveolar macrophages and other tissue macrophages, especially the studies by Curtis and colleagues (31) and Peters-Golden et al. (32, 33, 34, 35, 36, 37). This study focuses on human alveolar macrophages and does not attempt to define which other macrophages exhibit the described phenotype. We consider this to be an important component of further studies.

In this study, we investigated the novel hypothesis that in unstimulated human alveolar macrophages, long-term viability is maintained via ERK-dependent effects on the phosphatase, PP1{alpha}, and protein translation. We demonstrate that inhibition of ERK results in decreased protein translation, JNK-dependent inactivation of PP1{alpha}, and phosphorylation of eIF2{alpha}. The end result of these events (downstream of ERK inhibition) is shortened survival of alveolar macrophages, due, at least in part, to decreased protein translation.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Materials

Chemicals were obtained from Sigma-Aldrich. The MEK inhibitor UO126 (662005), p38 inhibitor SB203580 (559389), JNK inhibitor II (SP600125 (420119)), PP1{alpha} inhibitor tautomycin (580551), ERK activation inhibitor peptide II (328005), actinomycin D (114666), and recombinant rabbit muscle PP1{alpha} isoform (539493) were obtained from Calbiochem. Recombinant human active JNK2{alpha}2 peptide (PHO3011) was purchased from BioSource International. Radionuclides [35S]methionine (NEG-709A) and [{gamma}-32P]ATP Easytides (NEG-502Z) were purchased from PerkinElmer. Ethidium homodimer (E1169) was obtained from Molecular Probes. Western blotting reagents include Calbiochem’s phosphatase inhibitor mixture (524625), complete minitab protease inhibitors (11836170001) from Roche, ECL (RPN2106) and ECL+ (RPN2132) chemiluminescent detection reagents from Amersham Biosciences, and acrylimide (161-0158), buffers (161-0798 and 161-0799), polyvinylidene difluoride (PVDF) membranes (162-0174), and Bradford protein assay reagent (500-0006) from Bio-Rad. Abs used in this study were obtained from a variety of sources. Phosphorylation-specific Abs to eIF2-{alpha} (9721), PP1{alpha} (2581), and ERK (9101) were obtained from Cell Signaling Technology, and JNK (559309) from Calbiochem. Cleaved caspase 7 (9491) and 9 (9509) and cleaved poly(ADP-ribose) polymerase (PARP) (9541) and eIF2-{alpha} (nonphospho) (9722) Abs were also obtained from Cell Signaling Technology. PP1{alpha} (sc-6105), JNK2 (7345), PP1{alpha} agarose conjugate (sc-6105-AC), HRP-conjugated Abs anti-rabbit (sc-2004), anti-mouse (sc-2005), and anti-goat (sc-2020) were all obtained from Santa Cruz Biotechnology. We tried a number of MAPK phosphatase-7 (MKP-7) Abs, including ones from Abcam (ab15698), Imgenix (IMX-3042), and an Ab provided by M. Collins (Royal Free and University College Medical School, London, U.K.). We found all of these Abs problematic in terms of visualizing endogenous proteins. We finally ended up using an Ab from Calbiochem (MKP-7; PC726). beta-Actin (A5316) was obtained from Sigma-Aldrich. Culture medium used in experiments was serum-free RPMI 1640 tissue culture medium plus Glutamax (61870-036) from Invitrogen Life Technologies and methionine/cysteine-free RPMI 1640 medium (R7513) from Sigma-Aldrich. Kits used in this study were pNPP Phosphatase Activity Kit (POPN-10K) from BioAssay Systems and CellTiter-Glo Luminescent Cell Viability Assay (G7571) from Promega.

Isolation of human alveolar macrophages

Alveolar macrophages were obtained from normal nonsmoking volunteers, as previously described (38). Briefly, normal volunteers with a lifetime nonsmoking history, no acute or chronic illness, and no current medications underwent bronchoalveolar lavage. The cell pellet was washed twice in HBSS without Ca2+ and Mg2+ and suspended in complete RPMI 1640 medium with glutamax (Invitrogen Life Technologies) and added gentamicin (80 µg/ml). Cells were cultured in special nonadherent plates from Costar (3471, 3473) to minimize effect of adherence on signaling. All experiments were conducted in serum-free conditions. Differential cell counts were determined using a Wright-Giemsa-stained cytocentrifuge preparation. All cell preparations had between 90 and 100% alveolar macrophages. This study was approved by the Committee for Investigations Involving Human Subjects at the University of Iowa.

Methionine labeling

Alveolar macrophages were put into culture in low adherent 100-mm plates (106 cells/ml RPMI 1640 with glutamax and gentamicin). Actinomycin D (Calbiochem) was added to prevent any new transcription of proteins. After a time period for isolation recovery, the cells were transferred to methionine-free RPMI 1640 (Sigma-Aldrich) and cultured for 30 min. [35S]Methionine was added (5 mCi/0.5 ml, 0.2 mCi/ml prewarmed methionine-free RPMI 1640), and the cells were cultured for various times before harvesting. Cells were harvested using standard protein isolation procedures, as outlined below. Protein levels were measured, and a SDS-PAGE gel was run. The gels were dried and autoradiographs were obtained showing 35S-labeled proteins.

TCA precipitation of labeled proteins

Some of the protein from the 35S-labeling experiments was used to obtain relative 35S counts of the labeled proteins. A total of 20 µl of the 35S-labeled cell suspension was added to 100 µl of BSA (1 mg/ml) and sodium nitrate (NaN3, 0.02%). One milliliter of ice-cold 10% w/v TCA was added to each tube, and the samples were vortexed vigorously. The solution was filtered through a 2.5-cm glass microfiber filter (Millipore) and the filters were washed twice with 5 ml of ice-cold 10% TCA. The discs were washed two more times in ethanol, dried, and placed in vials with 5–10 ml of scintillation mixture, and radioactivity was determined with a scintillation counter set on a wide open channel. Starting values (total) were determined by spotting 20 µl of the original cell lysate onto a filter and counting. Calculations were as follows: sample counts/total counts x 100 yields percentage of 35S incorporation. Fold increase was determined by dividing experimental sample values by control values.

Whole cell protein isolation

Whole cell protein was obtained by lysing the cells on ice for 20 min in 200 µl of lysis buffer (0.05 M Tris (pH 7.4), 0.15M NaCl, 1% Nonidet P-40, with added protease and phosphatase inhibitors: 1 protease minitab (Roche Biochemicals)/10 ml and 100 µl of 100x phosphatase inhibitor mixture (Calbiochem)/10 ml). The lysates were sonicated for 20 s, kept at 4°C for 30 min, and spun at 15,000 x g for 10 min, and the supernatant was saved. Protein determinations were made using the Bradford protein assay from Bio-Rad. Cell lysates were stored at –70°C until use.

Immunoprecipitation of cellular proteins

For immunoprecipitation, lysates were combined with 25 µg of PP1{alpha} agarose conjugate (Santa Cruz Biotechnology) overnight rotating at 4 degrees. Beads were washed three times with lysis buffer. For Western blot analysis, the beads were suspended in 50 µl of 2x sample buffer and heated for 5 min at 95 degrees. The beads were spun down and proteins were analyzed by SDS-PAGE. Western blot protocol was followed, as described below. Coimmunoprecipitations were determined by staining the resulting blots for proteins other than the one pulled down. Equal loading was determined by stripping the blots and reprobing for the immunoprecipitated protein.

Western blot analysis

Western blot analysis for the presence of particular proteins or for phosphorylated forms of proteins was performed, as previously described (39). Briefly, 30 µg of protein was mixed 1:1 with 2x sample buffer (20% glycerol, 4% SDS, 10% 2-ME, 0.05% bromphenol blue, and 1.25 M Tris (pH 6.8)), loaded onto a 10% SDS-PAGE gel, and run at 110 V for 2 h. Cell proteins were transferred to PVDF membranes with a Bio-Rad semidry transfer system, according to the manufacturer’s instructions. Equal loading of the protein groups on the blots was evaluated using Ponceaus S (Sigma-Aldrich), a staining solution designed for staining total proteins on PVDF membranes. The PVDF was then blocked with 5% milk in TTBS (TBS with 0.1% Tween 20) for 1 h, washed, and then incubated with the primary Ab at dilutions of 1/500 to 1/2,000 overnight. The blots were washed four times with TTBS and incubated for 1 h with HRP-conjugated anti-IgG Ab (1/5,000 to 1/20,000). Immunoreactive bands were developed using a chemiluminescent substrate, ECL Plus or ECL (Amersham Biosciences). An autoradiograph was obtained, with exposure times of 10 s to 2 min. Protein levels were quantified using a FluorS scanner and Quantity One software for analysis (Bio-Rad). The data were analyzed, and statistics were performed using Graphpad software. Densitometry is expressed as fold increase (experimental value/control value).

Phosphatase activity assay

Phosphatase activity was measured using a pNPP phosphatase assay kit from BioAssay Systems. To measure PP1{alpha} phosphatase activity, PP1{alpha} was immunoprecipitated from whole cell lysates (human alveolar macrophages) using microcystin-Sepharose beads or PP1{alpha} Ab/protein A-Separose beads. Serial 2-fold dilutions of the washed beads were made in 100 mM Tris-HCl (pH 7.5) and 10 mM MgCl2. A total of 50 µl of each dilution was placed into a 96-well plate. pNPP substrate solution (50 µl) was then added to each well. After 5–30 min, the absorbance was read at 405 nM. Dilutions that fit into a linear range of purified standard (PP1{alpha}) were used to acquire data. Data are presented as OD units.

Cell survival analysis

For analysis of cell survival, alveolar macrophages were cultured in six-well tissue culture plates with or without pathway inhibitors (ERK, U0126 at 20 µM or ERK activation inhibitor peptide II (Calbiochem) at 50 µM) for the described times. Triplicate cultures were performed on all experiments. After the incubation period, the cells were stained with ethidium homodimer (Molecular Probes) at 8 µM, and images were obtained of both bright field and fluorescence using a Leica DMRB microscope equipped with a Qimaging RETICA 1300 digital camera and imaging system. After obtaining images, the percentage of EthD-1-positive cells was determined. Quantification was by direct cell count. Two hundred cells were counted from a minimum of four different fields. Average viability was determined and statistics were performed using GraphPad software.

ATP assay

Cell survival was also monitored by using CellTiter-Glo Luminescent Cell Viability Assay from Promega. Alveolar macrophages were cultured (1 million alveolar macrophages treated with either U0126 or ERK Activation Inhibitor Peptide II for 6 or 24 h) in 24-well plates. ATP, signaling the presence of metabolically active cells, was measured by bringing the plate to room temperature and adding CellTiter-Glo directly to each well. The plate was mixed on an orbital shaker to induce cell lysis and then the sample was read in a luminometer (integration time of 1 s). Data are presented as mean ± SE of luminescent readings from three separate experiments.

In vitro kinase assay

To evaluate PP1{alpha} phosphorylation, 250 ng of recombinant human active JNK2{alpha}2 peptide and 10 µg of recombinant rabbit muscle PP1{alpha} isoform were combined with 5 µCi of ATP (32) to evaluate the ability of JNK2 to phosphorylate PP1{alpha}. The PP1{alpha} inhibitor tautomycin (1 µM) was included in the reaction buffer (20 mM MOPS, 25 mM glycerol phosphate, 1 mM NaVO4, 5 mM EGTA, and 1 mM DTT). The experiment was conducted with JNK2{alpha}2 peptide alone; PP1{alpha} isoform alone; JNK2{alpha}2 peptide and PP1{alpha} isoform; and JNK2{alpha}2 peptide, PP1{alpha} isoform, and the JNK inhibitor SP600125 at 1 µM. Samples were incubated at 30 degrees for 20 min. Equal volume of 2x sample buffer was added at the end of the incubation, and samples were run on a 10% acrylimide gel, transferred to PVDF membrane, and visualized on a phosphor imager (Bio-Rad; Quantity One software).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Inhibition of ERK decreases protein translation

Human alveolar macrophages were placed in culture with and without the MEK inhibitor (U0126) for 2 h. During the last 30 min of culture, the cells were moved to methionine-deficient medium for 30 min (U0126 was replaced where appropriate). Cells were then treated with [35S]methionine and actinomycin D (to block transcription) and cultured for additional 2 h. Whole cell lysates were obtained and an aliquot was run out on a 10% SDS-PAGE gel. The gel was dried and an autoradiogram was obtained. Fig. 1 demonstrates that ERK inhibition results in decreased translation of multiple proteins. Also shown are data from three separate experiments in which TCA-precipitable proteins were isolated from the lysate and 35S counts were analyzed. Data are presented as fold difference (U0126/control). The graph demonstrates that in conditions in which transcription is frozen (actinomycin treatment), U0126 decreases the amount of new protein production. To confirm the presence of baseline ERK activity, three sets of macrophages were cultured with U0126 for 1 h. Whole cell lysates were obtained and ERK activity was monitored by Western blot analysis for the phosphorylated form of the protein. Fig. 1B demonstrates significant baseline ERK activity in human alveolar macrophages. As a composite, these data suggest that in alveolar macrophages there is constitutive ERK activity that plays an important role in maintaining ongoing protein translation. To examine the specificity of U0126, we treated alveolar macrophages with U0126 for 1 h and examined activity of the MAPK, p38, and the PI3K pathway component, Akt. Fig. 1C demonstrates that 1 h of U0126 completely blocks baseline ERK activity, has some negative effect on p38 activity, and has no effect on the activity of Akt. The effect of U0126 on JNK activity is not shown in Fig. 1C, as the activation of JNK by U0126 is a part of this study, and is shown in Figs. 5 and 6. Inhibition of ERK increases phosphorylation of eIF2{alpha}. Protein translation is primarily regulated at initiation. One major regulatory pathway is the eIF4F pathway, which recruits mRNAs with 5' caps to the ribosome. The other major pathway is the eIF2 pathway, which brings the start methionine (Met-tRNAimet) to the ribosome. When we examined the eIF4F pathway (eIF4E, 4EBP-1, eIF4A, eIF4B, and eIF4G) for alterations in activating and inhibiting phosphorylations after ERK inhibition, we found little change (data not shown). This is despite the described role of ERK as an upstream activator of Mnk1, which phosphorylates eIF4E. However, when we examined phosphorylation of eIF2{alpha} on serine 51, an inhibiting phosphorylation, we found significant and prolonged phosphorylation of eIF2{alpha} after U0126 (Fig. 2A). Densitometry from the three separate experiments is also shown. It is important to note that there is individual variation among the donors. In some cases, the eIF2{alpha} phosphorylation began as early as 15 min after U0126 and continued out to 24 h. In other cases, the time of eIF2{alpha} inhibition was more restricted. One possible cause of the discrepancies may be varied induction of GADD34, a PP1 regulator (and negative feedback mechanism (21, 29)) induced following eIF2{alpha} phosphorylation. We found various levels of GADD34 induction in the different donors (data not shown). This would contribute to altered duration of the eIF2{alpha} phosphorylation. In all cases, U0126 caused a prolonged phosphorylation of eIF2{alpha} (see Fig. 2D).


Figure 1
View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 1. A, Inhibition of ERK decreases protein translation rates. Human alveolar macrophages were put in culture with and without U0126 (20 µM) for 2 h. During the last 30 min of this culture time, the cells were moved to methionine-free medium (U0126 replaced where needed). For the labeling period, the following was added: actinomycin D (10 µM), [35S]methionine (0.2 mCi/ml), and in some cases U0126 (20 µM). Cells were incubated for a further 2 h, and then whole cell lysates were obtained and an SDS-PAGE gel was run, dried, and visualized on a phosphor imager. For the TCA data, lysates from three separate experiments were treated with TCA to precipitate proteins, the samples were run through a Millipore filter, and the precipitated protein was counted on a liquid scintillation counter. The graph shows percentage of control based on the control value of experiment 1 control (control/sample x 100) (mean ± SE). B, Human alveolar macrophages have constitutive ERK activity. Human alveolar macrophages were placed in culture for 1 h immediately after isolation with and without added U0126 (20 µM). Whole cell lysates were obtained and Western blot analysis was performed for the active (phosphorylated) form of ERK. On the right is composite densitometry from the three samples. The data demonstrate constitutive ERK activity in human alveolar macrophages. C, U0126 primarily inhibits ERK. Human alveolar macrophages were placed in culture with and without U0126 (20 µM) for 1 h. Specificity was examined by determining the effect of U0126 on the activity of ERK (phosphorylated on threonine 202 and tyrosine 204), p38 (phosphorylated on threonine 180 and tyrosine 182), and Akt (phosphorylated on serine 473) by Western blot analysis. (The relationship between ERK inhibition and JNK activity is addressed later in the manuscript.)

 

Figure 5
View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 5. Inhibition of ERK activates JNK and decreases amounts of the JNK phosphatase, MKP-7. A, Human alveolar macrophages were cultured with either U0126 (20 µM) or a cell-permeable ERK inhibitory peptide (50 µM) for 1 or 3 h. Whole cell lysates were obtained and Western blot analysis was performed using an Ab specific for JNK phosphorylated on threonine 183 and tyrosine 185. B, Human alveolar macrophages were cultured with an ERK inhibitor, U0126 (20 µM), for 1 or 3 h. Whole cell lysates were obtained and Western blot analysis was performed using an Ab specific for total MKP-7.

 

Figure 6
View larger version (51K):
[in this window]
[in a new window]
  		FIGURE 6. A, Active JNK phosphorylates PP1{alpha} in vitro. A total of 250 ng of active JNK2 (JNK2a2 aa 2–424 produced in Escherichia coli with an N-terminal polyhistidine tag and purified via sequential chromatography) was mixed in a 1.5-ml microtube with 10 µg of PP1{alpha} (PP1{alpha} isoform from rabbit muscle (sequence around the threonine 320 site is identical with human sequence (<www.ncbi.nlm.nih.gov/BLAST>) in buffer A (20 mM MOPS, 25 mM beta glycerol phosphate, 1 mM NaVO4, 5 mM EGTA, 1 mM DTT, and 1 µM tautomycin) with added 5 µCi of ATP in 0.5 mM cold ATP buffer/buffer A (total volume = 40 µl). Individual samples had variations of possible proteins (JNK alone, PP1{alpha} alone, both, and both with added JNK inhibitor, SP600125, 10 µM). The microtubes were vortexed gently and incubated at room temperature for 30 min. A total of 40 µl of Western sample buffer was added, and the samples were run out on a 10% SDS-PAGE gel. The finished gel was transferred to a PVDF membrane, and radioactive bands were identified by phosphor imager. Equal loading of the PP1{alpha} protein was confirmed by Western blot analysis using an Ab specific for PP1{alpha}. B, Inhibition of ERK results in binding of active JNK to PP1{alpha}. Human alveolar macrophages were cultured with U0126 (20 µM) for 1 h. Whole cell lysates were obtained and PP1{alpha} was immunoprecipitated. Western blot analysis was then performed for the following proteins: JNK (whole protein), active JNK (phosphorylated on threonine 183 and tyrosine 185), and PP1{alpha} (loading control).

 

Figure 2
View larger version (50K):
[in this window]
[in a new window]
  		FIGURE 2. Inhibition of ERK increases phosphorylation of eIF2{alpha} on serine 51. A, Three sets of human alveolar macrophages were cultured with U0126 (20 µM) for various lengths of time. Whole cell lysates were obtained and Western blot analysis was performed using an Ab specific for eIF2{alpha} phosphorylated on serine 51. Composite densitometry of the three experiments is shown on the right. B, Human alveolar macrophages were exposed to varying doses of U0126 (0.2, 2, and 20 µM) for 1 h. Whole cell lysates were obtained and Western blot analysis was performed for phosphorylated eIF2a (serine 51) and active ERK. Equal loading of the proteins is demonstrated by staining of the blots for beta-actin. C, Human alveolar macrophages were cultured with a cell-permeable ERK inhibitory peptide (50 µM) for various lengths of time. Whole cell lysates were obtained and Western blot analysis was performed using an Ab specific for eIF2{alpha} phosphorylated on serine 51. D, Human alveolar macrophages were cultured with an ERK inhibitor (U0126, 20 µM) for prolonged time periods. Whole cell lysates were obtained and Western blot analysis was performed using an Ab specific for eIF2{alpha} phosphorylated on serine 51.

 
We treated normal alveolar macrophages with varying amounts of U0126. Fig. 2B demonstrates that U0126 causes significant phosphorylation of eIF2{alpha} over multiple concentrations. The inhibitory effect of U0126 on ERK phosphorylation is shown as a control. To determine that the U0126 observation was not due to an artifact of the chemical inhibitor, we performed the same experiment using a small peptide ERK inhibitor. This inhibitor is a 13-aa peptide from the ERK upstream kinase, MEK, fused to the HIV-TAT membrane translocation peptide via a glycine linker (H-GYGRKKRRQRRR-G-MPKKKPTPIQ LNP-NH2). The peptide is membrane permeable and interferes with ERK/MEK interactions. Fig. 2C demonstrates that, as with U0126, the ERK inhibitory peptide also increased eIF2{alpha} phosphorylation on serine 51. Finally, we asked whether the increased eIF2{alpha} phosphorylation generated by ERK inhibition was a transient or prolonged event. Fig. 2D shows that the increase in eIF2{alpha} phosphorylation on serine 51 after ERK inhibition is a prolonged event (extending out to 24 h). Consistent with the discussion in the paragraph above, there was some variability in the duration of the eIF2{alpha}. However, in most cases, U0126 caused prolonged phosphorylation of eIF2{alpha}. The data in this study demonstrate, consistent with the effects of ERK inhibition on translation, that eIF2{alpha} is phosphorylated on the inhibitory serine 51 site for a prolonged period following ERK inhibition.

Inhibition of ERK decreases PP1 activity

EIF2{alpha} phosphorylation is regulated by the combined activity of upstream kinases (PKR, PERK, GCN2, and HRI). It is also regulated by the dephosphorylating activity of PP1{alpha}. We initially examined the effect of ERK inhibition on the upstream kinases and did not find any significant effect (data not shown). We then examined the effect of ERK inhibition on PP1{alpha} activity. Immunoprecipitated PP1{alpha} was evaluated for in vitro phosphatase activity using pNPP as a substrate. ERK inhibition significantly decreased PP1{alpha} activity (Fig. 3A). To further examine whether phosphatase inhibition was sufficient to increase phosphorylation of eIF2{alpha}, we treated human alveolar macrophages with the PP1-specific inhibitor, tautomycin. Fig. 3B shows that inhibition of PP1 (tautomycin) results in phosphorylation of eIF2{alpha}. This suggests that inhibiting PP1 is sufficient to increase eIF2{alpha} phosphorylation in human alveolar macrophages and that there is enough baseline activity in the upstream kinases to assure phosphorylation of eIF2{alpha} in conditions in which PP1 is inhibited. As a composite, these data suggest that ERK inhibition in alveolar macrophages leads to a decrease in PP1{alpha} activity, which is sufficient to increase the phosphorylation of eIF2{alpha} at serine 51.


Figure 3
View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 3. A, Inhibition of ERK decreases PP1{alpha} activity. Human alveolar macrophages were cultured for 1 h with either U0126 (20 µM) or the PP1 inhibitor, tautomycin (1 µM). Whole cell lysates were obtained and PP1{alpha} was immunoprecipitated. The immunoprecipitated PP1{alpha} was used in a phosphatase activity assay (pNPP substrate solution). Data are presented as total OD units (340 nM) after a 30-min incubation of immunoprecipitated phosphatase and substrate. B, Blocking PP1{alpha} activity is sufficient to induce eIF2{alpha} phosphorylation. Human alveolar macrophages were cultured with PP1{alpha} inhibitor (tautomycin, 0.2–2.0 µM) for 1 h. Whole cell lysates were obtained and Western blot analysis was performed using an Ab specific for eIF2{alpha} phosphorylated on serine 51. Densitometry shown as arbitrary units is on the right.

 
ERK inhibition increases PP1{alpha} phosphorylation

To determine a possible mechanism by which ERK regulates PP1 activity, we evaluated the effect of ERK inhibition on an inhibiting phosphorylation of the {alpha} catalytic subunit of PP1 (threonine 320). Fig. 4A demonstrates that in alveolar macrophages, ERK inhibition increases phosphorylation of PP1{alpha}, a phosphorylation event that inhibits activity of PP1{alpha}.


Figure 4
View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 4. A, Inhibition of ERK induces phosphorylation of PP1{alpha} on threonine 320. Human alveolar macrophages were cultured with an ERK inhibitor (U0126, 20 µM) for 1 or 3 h. Whole cell lysates were obtained and Western blot analysis was performed using an Ab specific for PP1{alpha} phosphorylated on threonine 320. B, JNK inhibition (and not p38 inhibition) reverses the effect of U0126 on eIF2{alpha}. Human alveolar macrophages were cultured with an ERK inhibitor (U0126, 20 µM) for 1 h. In some groups, either p38 (SB20358, 20 µM) or JNK (SP600125, 1 µM) was also inhibited. Whole cell lysates were obtained and Western blot analysis was performed using an Ab specific for eIF2{alpha} phosphorylated on serine 51.

 
The phosphorylation site on PP1{alpha} (threonine 320) is a consensus MAPK substrate site (PX(S/T)P)(PP1{alpha}: 315 GGRPITPPRNS 325). The MAPK consensus sequence is underlined and in italics. The threonine phosphorylation site is shown in bold. Because ERK was inhibited in these studies, it is not a potential upstream kinase. The only described upstream kinases for this site are the cell cycle regulatory kinases, cyclin-dependent kinase 1 (Cdk1) and Cdk2 (40, 41). We could find no sign in any change in Cdk1 or Cdk2 activity with ERK inhibition (data not shown). This is consistent with a recent study by Romerio and Zella (42), demonstrating that IFN-{alpha} decreases ERK activity leading to decreased Cdk2 activity. To investigate other possible upstream kinases of the PP1{alpha} site, we evaluated the effect of inhibiting other MAPKs together with the ERK inhibition. Fig. 4B demonstrates that inhibiting p38 (SB203580) had no effect on the U0126-induced eIF2{alpha} phosphorylation. In contrast, blocking JNK activity at the same time as U0126 resulted in a loss of the U0126-induced phosphorylation of eIF2{alpha}. As a composite, these experiments demonstrate that inhibition of baseline ERK activity in alveolar macrophages results in phosphorylation of PP1{alpha} on threonine 320 and that JNK activity is required for the ERK inhibition-dependent phosphorylation of eIF2{alpha}.

ERK inhibition results in activation of JNK and a decrease in the JNK phosphatase, MKP-7

We next asked whether ERK inhibition increased JNK activity. In Fig. 5A, we demonstrate that ERK inhibition by either U0126 or an ERK inhibitory peptide significantly increased JNK activity. In Fig. 5B, we examine the effect of ERK inhibition on amounts of MKP-7. ERK inhibition decreased total MKP-7 protein amounts. These data suggest that at baseline in alveolar macrophages, active ERK decreases JNK activity by phosphorylating and protecting from degradation the JNK phosphatase, MKP-7.

JNK phosphorylates PP1{alpha} in vitro and complexes with eIF2{alpha} and PP1{alpha}

To test the hypothesis that JNK could be a PP1{alpha} threonine 320 kinase, we performed an in vitro assay using purified active JNK and purified catalytic domain of PP1{alpha}. Isolated proteins were mixed with a kinase buffer and 32ATP. The samples were then run on an SDS-PAGE gel, the gel was transferred to PVDF membrane, and radioactivity was determined using a phosphor imager. Fig. 6A demonstrates that in vitro, JNK can phosphorylate PP1{alpha} on threonine 320. We next asked whether ERK inhibition would bring PP1{alpha} and JNK together in a complex. Alveolar macrophages were treated with an ERK inhibitor and then PP1{alpha} immunoprecipitated. The protein complex was then analyzed for JNK binding. Fig. 6B demonstrates that JNK is recruited to PP1{alpha} under conditions of ERK inhibition. It is also clear that it is the active form of JNK2 that is associating with PP1{alpha} after ERK inhibition.

ERK inhibition shortens survival of human alveolar macrophages

Our initial hypothesis was that baseline ERK activity in alveolar macrophages is an important survival pathway. Having demonstrated that ERK inhibition leads to a decrease in global protein translation, we then evaluated the effect of ERK inhibition on alveolar macrophage survival. Fig. 7 demonstrates that inhibition of ERK increases markers of apoptosis and death in alveolar macrophages. Fig. 7A demonstrates that ERK inhibition with U0126 results in cleaved caspase 7, cleaved caspase 9, and cleaved PARP, peaking at 24 h of U0126 exposure. Fig. 7B demonstrates that U0126 increases the membrane permeability of alveolar macrophages, as demonstrated by ethidium homodimer uptake (shown both by a photomicrograph and by cell counts from three separate experiments). In Fig. 7C, we evaluated ATP depletion as a marker of viability. Exposure to both U0126 and the ERK inhibitory peptide caused a significant drop in ATP levels, from 40 to 70% of control at 6 h and from 2 to 5% of control at 24 h. The ATP data are consistent with the enhanced caspase and PARP cleavage we saw at 24 h of U0126 exposure. As a composite, the data demonstrate that baseline ERK activity is crucial for the survival of human alveolar macrophages.


Figure 7
View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 7. Inhibition of ERK shortens survival of alveolar macrophages. A, Human alveolar macrophages were cultured with U0126 (20 µM) for 1, 3, 6, and 24 h. Whole cell lysates were obtained and Western blot analysis was performed using Abs specific for cleaved caspase 7, cleaved caspase 9, and cleaved PARP. Equal loading of proteins is demonstrated with a beta-actin blot. B, Human alveolar macrophages were cultured with U0126 (20 µM) for 6 or 24 h. Cell survival was analyzed by EthD-1 cell entry. The figure shows the cell monolayer with the fluorescent photomicrographs of the EthD-1-positive cells superimposed on the brightfield images. The images are representative of three separate experiments. The graph depicts the percentage of dead cells found at both 6 and 24 h post-U0126 exposure. The data are from three separate experiments. C, Human alveolar macrophages were cultured with either U0126 (20 µM) or a cell-permeable ERK inhibitory peptide (50 µM) for 6 or 24 h. At the end of the incubation period, total ATP was measured using an ATP luminescence assay. Data are presented as arbitrary light units. At both time periods and with both inhibitors, control values were significantly different from experimental values (p < 0.01).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The alveolar macrophage maintains baseline activity of two pathways that contribute to prolonged survival. We have shown previously that both the PI3K/Akt and ERK pathways are activated at baseline in alveolar macrophages (3). The prosurvival effects of Akt are well described and were not the subject of these studies. In contrast, little is known about the survival effects of ERK (10, 43, 44, 45). In this study, we examined the role of ERK activity in maintaining adequate levels of protein translation, a necessary condition for cell survival. We found that inhibition of ERK significantly decreased protein translation in alveolar macrophages. Due to the rich oxidant and pathogen exposure in the lung, it is our hypothesis that this is a lung-specific effect. However, we have not yet performed the macrophage comparative experiments that will allow for that conclusion. We have shown previously that survival pathway activity is different between human alveolar macrophages and their precursor cells, blood monocytes (3, 30). We have not yet compared alveolar macrophages and other tissue macrophages. These experiments are part of ongoing projects.

Regulation of translation primarily occurs at the initiation step (17, 46). One important pathway is recruitment of ribosomes to mRNA by the eIF4F complex. Despite described links between ERK and eIF4E (20, 47), we found no obvious effect of ERK inhibition on this complex in alveolar macrophages. Another important pathway in the initiation process is binding the initiator Met-tRNAimet to the P site of the small ribosomal subunit by the eIF2 complex (17). When we examined the effect of ERK inhibition on the eIF2 complex, we found a significant change in the phosphorylation status of eIF2{alpha} (active eIF2{alpha} is hypophosphorylated on serine 51). Phosphorylation of eIF2{alpha} normally occurs as part of a stress response (nutrient deprivation, viral infection, ER stress, and low heme levels). In the case of ERK inhibition, we observed no changes in the activity of the stress-related upstream kinases (data not shown). We did, however, observe marked changes in activity of the phosphatase, PP1{alpha}, which is responsible for maintaining eIF2{alpha} in a hypophosphorylated state (29)).

ERK inhibition resulted in decreased PP1{alpha} activity that was due to an increase in an inhibitory phosphorylation at a site on the catalytic unit of PP1{alpha} (threonine 320). Threonine 320 is a MAPK substrate consensus sequence. Therefore, we looked at other MAPKs as potential upstream kinases responsible for PP1{alpha} phosphorylation. We found that ERK inhibition increased activity of the MAPK, JNK. In addition, we found that active JNK can phosphorylate PP1{alpha} in vitro and that JNK inhibition reverses the increase in eIF2{alpha} phosphorylation seen with ERK inhibition. Finally, using a number of methods, we show that ERK inhibition significantly shortens survival of alveolar macrophages. (Fig. 8 contains a diagram demonstrating our hypothesis on the relationship among ERK, eIF2{alpha}, JNK, and PP1{alpha}.)


Figure 8
View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 8. Diagrammatic representation of the link among ERK, JNK, PP1{alpha}, eIF2{alpha}, and protein translation. In human alveolar macrophages, ERK decreases JNK activity. JNK activity can decrease PP1{alpha} phosphatase activity. With low JNK, the higher activity of PP1{alpha} maintains hypophosphorylated (active) eIF2{alpha}. Inhibition of ERK or PP1{alpha} leads to eIF2{alpha} phosphorylation and decreased protein translation. Ongoing protein translation (driven by ERK activity) contributes to the prolonged survival of these cells, despite the frequently stressful conditions found in the lung.

 
Translation inhibition (specifically phosphorylation of eIF2{alpha}) and apoptosis have been linked in other systems. One recent paper links apoptosis induced by proteosome inhibition to the phosphorylation of eIF2{alpha} by upstream kinases (48). These authors found a correlation between an increase in eIF2{alpha} phosphorylation and caspase activation and apoptosis. This is consistent with our observations.

In contrast to the proapoptotic effect of eIF2{alpha} phosphorylation, there are also data linking eIF2{alpha} phosphorylation to activation of the prosurvival transcription factor, NF-{kappa}B (23, 48, 49). One study by Jiang et al. (50) examined the hypothesis that NF-{kappa}B activity during ER stress requires temporary translational arrest to prevent the rapid resynthesis of the inhibitory subunit I{kappa}B{alpha}. The authors suggest that eIF2{alpha} phosphorylation is necessary for NF-{kappa}B activation. Our system differs in a variety of ways. For one, we have no significant induction of the upstream kinases (PERK, PKR, GCN2, and HRI). For another, the duration of phosphorylation of eIF2{alpha} with ERK inhibition is extremely long, and this is different from the normal stress response. Although ER stress temporarily inhibits most translation, it induces translation of a subset of stress-related proteins. One of these stress-related proteins is instrumental in reactivating PP1{alpha} and ending the eIF2{alpha} phosphorylation. This feedback mechanism is not operative in our system. We found no induction of GADD34 (the stress-related protein that activates PP1{alpha}). In our case, eIF2{alpha} phosphorylation has no endogenous shutoff mechanism as long as ERK is inactive and the extended shutdown of the translation apparatus leads to cell death.

Our data demonstrate a decrease in PP1{alpha} activity with ERK inhibition and the novel observation that this is linked to ERK inhibition-dependent activation of JNK. PP1{alpha} activity is regulated by its regulatory subunits. PP1{alpha} activity is also negatively regulated by phosphorylation at threonine 320 (40). There is only one previous study linking ERK to PP1. In a paper by Quevedo et al. (51), using neuronal cell cultures, insulin-like growth factor 1 was shown to induce PP1 activity via MEK/ERK activity. In this case, the endpoint is activation of eIF2B, not eIF2{alpha}. The Quevedo study does demonstrate that in another system, ERK can be upstream of PP1. Our data link ERK to PPI{alpha} via an effect on phosphorylation of PP1{alpha} on threonine 320 by JNK.

Our conclusion that PP1{alpha} phosphorylation is via JNK activation is supported by the following data: ERK inhibition by both chemical (U0126) inhibitor and cell-permeable inhibitory peptides results in JNK activation in alveolar macrophages. The threonine 320 site on PP1{alpha} is part of a consensus MAPK substrate sequence (PX(S/T)P). The kinases that preferentially phosphorylate this consensus sequence include: MAPKs (ERK, p38, and JNK isoforms), glycogen synthase-3, and Cdks (52). The upstream kinase is obviously not ERK as it is inhibited, and when we examined p38 we found that ERK inhibition in alveolar macrophages actually decreased p38 activity slightly. We also found no change in the activity of Cdk1, a previously described PP1{alpha} kinase (40). However, when we examined JNK activity, we found a significant increase in the level of JNK activity in ERK-inhibited alveolar macrophages. We also found that JNK could phosphorylate PP1{alpha} in vitro and that after ERK inhibition, JNK could be found in a complex with eIF2{alpha} and PP1{alpha}.

Our data suggest a mechanism for the increase in JNK activity. Previous studies have demonstrated a positive role for ERK activity in the stability of the dual phosphatase, MKP-7 (53, 54). The study by Katagiri et al. (53) demonstrates that ERK phosphorylates the JNK-specific dual phosphatase, MKP-7. The functional consequence of the ERK phosphorylation on serine 446 is to stabilize MKP-7 protein, allowing for its accumulation. MKP-7 has been demonstrated to preferentially dephosphorylate JNK (55). The role of dual specificity phosphatases in JNK activity is complicated. Along with the already discussed negative role of MKP-7 in JNK inactivation, Shen et al. (56) have described a novel dual specificity phosphatase, JSP-1, whose overexpression activates JNK. We don’t know at this point whether there is any link between ERK and JSP-1. Our data suggest a positive role for ERK activity in MKP-7 stability; however, due to the problems in visualizing the endogenous protein (see Ab information in Materials and Methods), a definitive link between ERK and MKP-1 in alveolar macrophages awaits future studies.

In human alveolar macrophages, we have found that ERK activity is a prosurvival phenomenon. That is not always the case. In the paper by Levinthal and DeFranco (57), glutamate-induced oxidative stress induces neuronal death in an ERK-dependent manner. These data suggest that the role of ERK in cell survival is stimulus and cell-type specific. JNK activity has also been linked to both cell survival and death. One study, consistent with our finding of a proapoptotic effect of JNK activity, is a study by Handley et al. (58). The Handley study demonstrates that oxidative stress-induced apoptosis requires JNK activity. Interestingly, they link JNK activity to inhibition of tyrosine phosphatases. Our study links JNK activation to inactivation of another class of phosphatases, the serine/threonine phosphatases (PP1{alpha}).

In contrast, a study by Himes et al. (59) shows that activation of JNK by CSF-1 is important in macrophage differentiation and survival. Although both our study and the Himes et al. (59) study are about macrophages and JNK, there are important differences between the two studies. The Himes et al. (59) study uses murine bone marrow-derived macrophages instead of human primary tissue macrophages (alveolar). They also are studying the effect of a growth factor, CSF-1, instead of homeostatic conditions. Furthermore, their inhibitor level is up to 10 times the amount used in our study (10–20 µM compared with 1 µM). We believe that the differences in species, model, and inhibitor use can explain the different survival outcomes in the two studies.

As a composite, our data demonstrate that in alveolar macrophages, baseline ERK activity maintains protein translation via the following novel pathway: ERK decreases JNK activity by stabilizing MPK-7. This, in turn, leads to activation of PP1{alpha} and maintenance of hypophosphorylated (active) eIF2{alpha} and translation. This positive effect of ERK on protein translation is consistent with the prolonged survival of human alveolar macrophages. Thus, this newly described role for ERK in alveolar macrophage homeostasis explains, in part, the survival characteristics of these cells.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a Department of Veterans Affairs Merit Review grant; National Institutes of Health Grants HL-60316, HL-077431, and HL079901-01A1; and Grant RR00059 from the General Clinical Research Centers Program, National Center for Research Resources, National Institutes of Health. Back

2 Address correspondence and reprint requests to Dr. Martha M. Monick, Division of Pulmonary, Critical Care, and Occupational Medicine, Room 100, Eckstein Medical Research Building, Carver College of Medicine, University of Iowa, Iowa City, IA 52242. E-mail address: martha-monick{at}uiowa.edu Back

3 Abbreviations used in this paper: eIF, eukaryotic initiation factor; Met-tRNAimet, initiator methionyl-tRNA; Cdk, cyclin-dependent kinase; ER, endoplasmic reticulum; GCN2, general control nonderepressing 2 kinase; HRI, heme-regulated inhibitor kinase; MKP, MAPK phosphatase; PARP, poly(ADP-ribose) polymerase; PERK, protein kinase R-like ER kinase; PKR, protein kinase R; PP1, protein phasphatase 1; PVDF, polyvinylidene difluoride. Back

Received for publication January 25, 2006. Accepted for publication May 11, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Thomas, E. D., R. E. Ramberg, G. E. Sale, R. S. Sparkes, D. W. Golde. 1976. Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science 192: 1016-1018. [Abstract/Free Full Text]
  2. Komuro, I., N. Keicho, A. Iwamoto, K. S. Akagawa. 2001. Human alveolar macrophages and granulocyte-macrophage colony-stimulating factor-induced monocyte-derived macrophages are resistant to H2O2 via their high basal and inducible levels of catalase activity. J. Biol. Chem. 276: 24360-24364. [Abstract/Free Full Text]
  3. Monick, M. M., R. K. Mallampalli, M. Bradford, D. McCoy, T. J. Gross, D. M. Flaherty, L. S. Powers, K. Cameron, S. Kelly, A. H. Merrill, Jr, G. W. Hunninghake. 2004. Cooperative prosurvival activity by ERK and Akt in human alveolar macrophages is dependent on high levels of acid ceramidase activity. J. Immunol. 173: 123-135. [Abstract/Free Full Text]
  4. Franke, T. F., D. R. Kaplan, L. C. Cantley. 1997. PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-434. [Medline]
  5. Nakamura, N., S. Ramaswamy, F. Vazquez, S. Signoretti, M. Loda, W. R. Sellers. 2000. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol. 20: 8969-8982. [Abstract/Free Full Text]
  6. Zugasti, O., W. Rul, P. Roux, C. Peyssonnaux, A. Eychene, T. F. Franke, P. Fort, U. Hibner. 2001. Raf-MEK-Erk cascade in anoikis is controlled by Rac1 and Cdc42 via Akt. Mol. Cell. Biol. 21: 6706-6717. [Abstract/Free Full Text]
  7. Chen, J., K. Fujii, L. Zhang, T. Roberts, H. Fu. 2001. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl. Acad. Sci. USA 98: 7783-7788. [Abstract/Free Full Text]
  8. Engedal, N., H. K. Blomhoff. 2003. Combined action of ERK and NF {kappa}B mediates the protective effect of phorbol ester on Fas-induced apoptosis in Jurkat cells. J. Biol. Chem. 278: 10934-10941. [Abstract/Free Full Text]
  9. Garcia, J., Y. Ye, V. Arranz, C. Letourneux, G. Pezeron, F. Porteu. 2002. IEX-1: a new ERK substrate involved in both ERK survival activity and ERK activation. EMBO J. 21: 5151-5163. [Medline]
  10. Hu, P., Z. Han, A. D. Couvillon, J. H. Exton. 2004. Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J. Biol. Chem. 279: 49420-49429. [Abstract/Free Full Text]
  11. Luciano, F., A. Jacquel, P. Colosetti, M. Herrant, S. Cagnol, G. Pages, P. Auberger. 2003. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22: 6785-6793. [Medline]
  12. Monick, M. M., A. B. Carter, G. Gudmundsson, L. J. Geist, G. W. Hunninghake. 1998. Changes in PKC isoforms in human alveolar macrophages compared with blood monocytes. Am. J. Physiol. 275: L389-L397. [Medline]
  13. Monick, M. M., A. B. Carter, D. M. Flaherty, M. W. Peterson, G. W. Hunninghake. 2000. Protein kinase C{zeta} plays a central role in activation of the p42/44 mitogen-activated protein kinase by endotoxin in alveolar macrophages. J. Immunol. 165: 4632-4639. [Abstract/Free Full Text]
  14. Allan, L. A., N. Morrice, S. Brady, G. Magee, S. Pathak, P. R. Clarke. 2003. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat. Cell Biol. 5: 647-654. [Medline]
  15. Reginato, M. J., K. R. Mills, J. K. Paulus, D. K. Lynch, D. C. Sgroi, J. Debnath, S. K. Muthuswamy, J. S. Brugge. 2003. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat. Cell Biol. 5: 733-740. [Medline]
  16. Phelps, M., A. Phillips, M. Darley, J. P. Blaydes. 2005. MEK-ERK signalling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J. Biol. Chem. 280: 16651-16658. [Abstract/Free Full Text]
  17. Holcik, M., N. Sonenberg. 2005. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 6: 318-327. [Medline]
  18. Holley, C. L., M. R. Olson, D. A. Colon-Ramos, S. Kornbluth. 2002. Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translational inhibition. Nat. Cell Biol. 4: 439-444. [Medline]
  19. Palaga, T., B. Osborne. 2002. The 3D’s of apoptosis: death, degradation and DIAPs. Nat. Cell Biol. 4: E149-E151. [Medline]
  20. Ueda, T., R. Watanabe-Fukunaga, H. Fukuyama, S. Nagata, R. Fukunaga. 2004. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol. Cell. Biol. 24: 6539-6549. [Abstract/Free Full Text]
  21. Kazemi, S., S. Papadopoulou, S. Li, Q. Su, S. Wang, A. Yoshimura, G. Matlashewski, T. E. Dever, A. E. Koromilas. 2004. Control of {alpha} subunit of eukaryotic translation initiation factor 2 (eIF2{alpha}) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2{alpha}-dependent gene expression and cell death. Mol. Cell. Biol. 24: 3415-3429. [Abstract/Free Full Text]
  22. Pestova, T. V., V. G. Kolupaeva, I. B. Lomakin, E. V. Pilipenko, I. N. Shatsky, V. I. Agol, C. U. Hellen. 2001. Molecular mechanisms of translation initiation in eukaryotes. Proc. Natl. Acad. Sci. USA 98: 7029-7036. [Abstract/Free Full Text]
  23. Deng, J., P. D. Lu, Y. Zhang, D. Scheuner, R. J. Kaufman, N. Sonenberg, H. P. Harding, D. Ron. 2004. Translational repression mediates activation of nuclear factor {kappa}B by phosphorylated translation initiation factor 2. Mol. Cell. Biol. 24: 10161-10168. [Abstract/Free Full Text]
  24. Gebauer, F., M. W. Hentze. 2004. Molecular mechanisms of translational control. Nat. Rev. Mol. Cell Biol. 5: 827-835. [Medline]
  25. Dey, M., B. Trieselmann, E. G. Locke, J. Lu, C. Cao, A. C. Dar, T. Krishnamoorthy, J. Dong, F. Sicheri, T. E. Dever. 2005. PKR and GCN2 kinases and guanine nucleotide exchange factor eukaryotic translation initiation factor 2B (eIF2B) recognize overlapping surfaces on eIF2{alpha}. Mol. Cell. Biol. 25: 3063-3075. [Abstract/Free Full Text]
  26. McEwen, E., N. Kedersha, B. Song, D. Scheuner, N. Gilks, A. Han, J. J. Chen, P. Anderson, R. J. Kaufman. 2005. Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation: induces stress granule formation, and mediates survival upon arsenite exposure. J. Biol. Chem. 280: 16925-16933. [Abstract/Free Full Text]
  27. Thomas, M., Z. Yu, N. Dadgar, S. Varambally, J. Yu, A. M. Chinnaiyan, A. P. Lieberman. 2005. The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. J. Biol. Chem. 280: 21264-21271. [Abstract/Free Full Text]
  28. Hao, S., J. W. Sharp, C. M. Ross-Inta, B. J. McDaniel, T. G. Anthony, R. C. Wek, D. R. Cavener, B. C. McGrath, J. B. Rudell, T. J. Koehnle, D. W. Gietzen. 2005. Uncharged tRNA and sensing of amino acid deficiency in mammalian piriform cortex. Science 307: 1776-1778. [Abstract/Free Full Text]
  29. Brush, M. H., D. C. Weiser, S. Shenolikar. 2003. Growth arrest and DNA damage-inducible protein GADD34 targets protein phosphatase 1{alpha} to the endoplasmic reticulum and promotes dephosphorylation of the {alpha} subunit of eukaryotic translation initiation factor 2. Mol. Cell. Biol. 23: 1292-1303. [Abstract/Free Full Text]
  30. Flaherty, D. M., M. M. Monick, S. L. Hinde. 2006. Human alveolar macrophages are deficient in PTEN: the role of endogenous oxidants. J. Biol. Chem. 281: 5058-5064. [Abstract/Free Full Text]
  31. Punturieri, A., R. S. Alviani, T. Polak, P. Copper, J. Sonstein, J. L. Curtis. 2004. Specific engagement of TLR4 or TLR3 does not lead to IFN-beta-mediated innate signal amplification and STAT1 phosphorylation in resident murine alveolar macrophages. J. Immunol. 173: 1033-1042. [Abstract/Free Full Text]
  32. Peters-Golden, M., R. W. McNish, R. Hyzy, C. Shelly, G. B. Toews. 1990. Alterations in the pattern of arachidonate metabolism accompany rat macrophage differentiation in the lung. J. Immunol. 144: 263-270. [Abstract]
  33. Peters-Golden, M., R. W. McNish, P. H. Sporn, K. Balazovich. 1991. Basal activation of protein kinase C in rat alveolar macrophages: implications for arachidonate metabolism. Am. J. Physiol. 261: L462-L471. [Medline]
  34. Peters-Golden, M., R. W. McNish. 1993. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Commun. 196: 147-153. [Medline]
  35. Wilborn, J., D. L. DeWitt, M. Peters-Golden. 1995. Expression and role of cyclooxygenase isoforms in alveolar and peritoneal macrophages. Am. J. Physiol. 268: L294-L301. [Medline]
  36. Phare, S. M., M. Peters-Golden, M. J. Coffey. 1998. Alveolar lining fluid regulates mononuclear phagocyte 5-lipoxygenase metabolism. Eur. Respir. J. 12: 1141-1146. [Abstract]
  37. Brock, T. G., R. W. McNish, P. Mancuso, M. J. Coffey, M. Peters-Golden. 2003. Prolonged lipopolysaccharide inhibits leukotriene synthesis in peritoneal macrophages: mediation by nitric oxide and prostaglandins. Prostaglandins Other Lipid Mediat. 71: 131-145. [Medline]
  38. Monick, M. M., A. B. Carter, G. W. Hunninghake. 1999. Human alveolar macrophages are markedly deficient in REF-1 and AP-1 DNA binding activity. J. Biol. Chem. 274: 18075-18080. [Abstract/Free Full Text]
  39. Thomas, K. W., M. M. Monick, J. M. Staber, T. Yarovinsky, A. B. Carter, G. W. Hunninghake. 2002. Respiratory syncytial virus inhibits apoptosis and induces NF-{kappa}B activity through a phosphatidylinositol 3-kinase-dependent pathway. J. Biol. Chem. 277: 492-501. [Abstract/Free Full Text]
  40. Liu, C. W., R. H. Wang, M. Dohadwala, A. H. Schonthal, E. Villa-Moruzzi, N. Berndt. 1999. Inhibitory phosphorylation of PP1{alpha} catalytic subunit during the G1/S transition. J. Biol. Chem. 274: 29470-29475. [Abstract/Free Full Text]
  41. Kwon, Y. G., S. Y. Lee, Y. Choi, P. Greengard, A. C. Nairn. 1997. Cell cycle-dependent phosphorylation of mammalian protein phosphatase 1 by cdc2 kinase. Proc. Natl. Acad. Sci. USA 94: 2168-2173. [Abstract/Free Full Text]
  42. Romerio, F., D. Zella. 2002. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-{alpha}2b. FASEB J. 16: 1680-1682. [Abstract/Free Full Text]
  43. Wang, T., Y. C. Hu, S. Dong, M. Fan, D. Tamae, M. Ozeki, Q. Gao, D. Gius, J. J. Li. 2005. Co-activation of ERK, NF-{kappa}B, and GADD45beta in response to ionizing radiation. J. Biol. Chem. 280: 12593-12601. [Abstract/Free Full Text]
  44. Harada, H., B. Quearry, A. Ruiz-Vela, S. J. Korsmeyer. 2004. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc. Natl. Acad. Sci. USA 101: 15313-15317. [Abstract/Free Full Text]
  45. Fernandez, C., A. M. Ramos, P. Sancho, D. Amran, E. de Blas, P. Aller. 2004. 12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells: regulation by extracellular signal-regulated protein kinases and glutathione. J. Biol. Chem. 279: 3877-3884. [Abstract/Free Full Text]
  46. Richter, J. D., N. Sonenberg. 2005. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433: 477-480. [Medline]
  47. Davies, C. C., J. Mason, M. J. Wakelam, L. S. Young, A. G. Eliopoulos. 2004. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J. Biol. Chem. 279: 1010-1019. [Abstract/Free Full Text]
  48. Jiang, H. Y., R. C. Wek. 2005. Phosphorylation of the {alpha}-subunit of the eukaryotic initiation factor-2 (eIF2{alpha}) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J. Biol. Chem. 280: 14189-14202.